Puhe Biopharma
Suzhou, China· Est.
A China-based biotech developing AI-driven small-molecule drugs for cancer and immune disorders with a global-first-tier pipeline.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
A China-based biotech developing AI-driven small-molecule drugs for cancer and immune disorders with a global-first-tier pipeline.
OncologyImmunologyMetabolic Diseases
Technology Platform
AI-integrated small-molecule drug discovery platform focused on high-barrier modalities including PROTACs, molecular glues, synthetic lethality, and next-generation kinase inhibitors.
Opportunities
Significant opportunity in advancing its novel mechanism pipeline (e.g., WRN inhibitor) in high-unmet-need oncology indications and expanding its global partnerships following the validation from the Bayer deal.
Risk Factors
As a young, pre-revenue company, it faces high execution risk in clinical development, intense competition in its focus areas, and dependency on the success of its platform technologies which are at early stages.
Competitive Landscape
Competes with numerous biotechs and pharmas in kinase inhibitors and novel modalities; differentiation lies in its integrated AI platform and focus on complex mechanisms like synthetic lethality (WRN) and protein degradation (PROTACs).